All In MedTech

FDA Clearance Tracker · P230014

Lumicell Direct Visualization System (DVS)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Apr 17, 2024 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Apr 17, 2024

Approved

Time to decision

369 days

Received Apr 14, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P230014
Device name
Lumicell Direct Visualization System (DVS)
Applicant location
Newton, MA
Received
Apr 14, 2023
Decided
Apr 17, 2024
Decision
Approved
Supplements
4 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code SAW

FDA's approval statement

As written in FDA's record.

APPROVAL FOR the Lumicell Direct Visualization System. This device is a fluorescence imaging system intended for use in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. The Lumicell Direct Visualization System is used with optical imaging agent LUMISIGHT (pegulicianine) for injection for fluorescence imaging of the lumpectomy cavity.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code SAW (Fluorescence imaging for breast cancer detection).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Lumicell, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.